Asenapine for Bipolar Depression
Sponsor: Merck Sharp & Dohme LLC
Terminated
funding ended due to recruitment delays
Other terminated trials from Merck Sharp & Dohme LLC
- Melanoma · Phase PHASE2 · Feb 2026
- Advanced Solid Tumor · Phase PHASE2 · Jan 2026
- Lung Cancer Metastatic · Phase PHASE1/PHASE2 · Dec 2025
- Advanced and Metastatic Urothelial Cancer · Phase PHASE2 · Sep 2025
- Malignant Solid Tumor · Phase PHASE1 · Aug 2025
More terminations from Merck Sharp & Dohme LLC
Other Bipolar Depression trials with similar outcome
A PHASE2 clinical study on Bipolar Depression, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 8 data snapshots since 2013. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Aug 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- University of Cincinnati
- University of Louisville
For direct contact, visit the study record on ClinicalTrials.gov .